Cartesian Therapeutics, Inc. Expected to Earn FY2027 Earnings of ($7.10) Per Share (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Cartesian Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($7.10) per share for the year. Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is ($1.50) per share.

A number of other equities research analysts also recently commented on the company. SVB Leerink started coverage on Cartesian Therapeutics in a report on Tuesday. They set an "outperform" rating and a $39.00 target price for the company. Needham & Company LLC started coverage on Cartesian Therapeutics in a report on Tuesday, April 9th. They issued a "buy" rating and a $42.00 price target for the company. Finally, HC Wainwright boosted their price target on Cartesian Therapeutics from $2.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday.

Cartesian Therapeutics Stock Up 0.6 %

Shares of Cartesian Therapeutics stock traded up $0.13 on Wednesday, reaching $20.72. 135,444 shares of the stock were exchanged, compared to its average volume of 44,291. Cartesian Therapeutics has a twelve month low of $11.66 and a twelve month high of $42.60. The company has a 50 day simple moving average of $19.29.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($2.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($2.10). Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%. The business had revenue of $8.27 million for the quarter.

Institutional Trading of Cartesian Therapeutics

A hedge fund recently bought a new stake in Cartesian Therapeutics stock. Hall Laurie J Trustee bought a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 52,775 shares of the company's stock, valued at approximately $34,000. Hall Laurie J Trustee owned approximately 0.98% of Cartesian Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 86.95% of the company's stock.

Insider Transactions at Cartesian Therapeutics

In other Cartesian Therapeutics news, Director Timothy A. Springer bought 21,612 shares of Cartesian Therapeutics stock in a transaction dated Thursday, March 14th. The stock was acquired at an average cost of $16.20 per share, with a total value of $350,114.40. Following the purchase, the director now directly owns 1,017,228 shares in the company, valued at approximately $16,479,093.60. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders acquired a total of 22,472 shares of company stock valued at $365,981 in the last three months. 31.20% of the stock is currently owned by company insiders.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.